We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+51.49%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
+$289M
Cap. Flow
+$29.7M
Cap. Flow %
2.6%
Top 10 Hldgs %
62.98%
Holding
38
New
8
Increased
7
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$31.1M
2
SYRE icon
Spyre Therapeutics
SYRE
+$24.4M
3
ARVN icon
Arvinas
ARVN
+$23.4M
4
ABVX
Abivax
ABVX
+$19.3M
5
PHVS icon
Pharvaris
PHVS
+$16.2M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$40.5M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$20.9M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$16.6M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.9M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
26
Dyne Therapeutics
DYN
$4.04B
$12M 1.05%
+900,000
New +$8.79M
VTGN icon
27
VistaGen Therapeutics
VTGN
$9.29M
$8.1M 0.71%
1,575,000
– –
THRD
28
DELISTED
Third Harmonic Bio
THRD
$7.75M 0.68%
706,706
-993,294
-58% -$7.87M
ADVM
29
DELISTED
Adverum Biotechnologies
ADVM
$7.53M 0.66%
1,000,000
– –
APGE icon
30
Apogee Therapeutics
APGE
$10.2B
$6.99M 0.61%
250,000
– –
SABS icon
31
SAB Biotherapeutics
SABS
$268M
$1.26M 0.11%
+183,175
New +$1.54M
DBVT
32
DBV Technologies
DBVT
$807M
$88.3K 0.01%
9,269
– –
CRNX icon
33
Crinetics Pharmaceuticals
CRNX
$8.86B
– –
-500,000
Closed -$14.9M
DAWN
34
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-739,661
Closed -$9.08M
IDYA icon
35
IDEAYA Biosciences
IDYA
$3.41B
– –
-775,000
Closed -$20.9M
MRSN
36
DELISTED
Mersana Therapeutics
MRSN
– –
-89,775
Closed -$2.85M
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-957,509
Closed -$13.9M
AMAM
38
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-3,518,556
Closed -$40.5M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Commodore Capital held 38 positions worth $1.14B, up 34% from $856M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Commodore Capital's Q4 2023 filing shows 8 new, 7 increased, 7 reduced and 6 closed positions. Its largest new stake was Arvinas: 1,000,000 shares worth $41.2M. The largest sale was Ambrx Biopharma Inc, an estimated $40.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Commodore Capital's largest Q4 2023 buy was Arvinas: 1,000,000 shares worth $41.2M.
  • Commodore Capital added most to Nuvalent in Q4 2023, an estimated $31.1M increase.
  • Commodore Capital's biggest Q4 2023 reduction was Rhythm Pharmaceuticals, cutting an estimated $16.6M.
  • Commodore Capital fully exited Ambrx Biopharma Inc in Q4 2023, selling an estimated $40.5M.
  • Commodore Capital's ten largest holdings make up 63% of its $1.14B portfolio in Q4 2023.
  • Commodore Capital opened 8 new positions and closed 6 in Q4 2023.
  • Commodore Capital's portfolio value rose 34% quarter-over-quarter to $1.14B.

Based on Commodore Capital's 13F filing for Q4 2023, filed 14 Feb 2024.